RESEARCH LETTER
Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study
二甲双胍联合磺脲类药物治疗失败的2型糖尿病患者中比较羟氯喹或者吡格列酮作为三线治疗药物的随机对照试验:一项初步研究
Funding information National Center for Advancing Translational Sciences, Grant/Award Number: UCLA CTSI UL1TR000124; National Institute of General Medical Sciences, Grant/Award Number: SC3GM113767; National Institute on Minority Health and Health Disparities, Grant/Award Number: U54 MD007598
Abstract
Highlights
- The anti-inflammatory agent, hydroxychloroquine, improved glycemic control in type 2 diabetes patients when used as a third-line agent added to metformin and a sulfonylurea.
- In comparison to pioglitazone, hydroxychloroquine lowered hemoglobin A1c levels less effectively and did not improve insulin sensitivity, but also did not cause any weight gain, hypoglycemia, or pedal edema.
- In this small, proof-of-concept study, hydroxychloroquine was well tolerated and may be an alternative treatment choice in combination with other agents.
